Document:

<PAGE>

                                                                    EXHIBIT 10.2

                      FOURTH AMENDMENT TO CREDIT AGREEMENT

         THIS FOURTH AMENDMENT TO CREDIT AGREEMENT (this "Amendment") is dated
as of June 18, 2004 by and among LIFEPOINT HOSPITALS HOLDINGS, INC. (the
"Borrower"); the financial institutions which are now, or in accordance with
SECTION 10.6 of the Credit Agreement (hereinafter described) hereafter, parties
to the Credit Agreement hereto by execution of the signature pages to the Credit
Agreement or otherwise (collectively, the "Lenders" and each individually, a
"Lender"); FLEET NATIONAL BANK, as administrative agent ("Administrative
Agent"), for the Lenders (in such capacity as Administrative Agent, together
with its successors and assigns in such capacity, the "Agent"); CREDIT LYONNAIS
NEW YORK BRANCH and SUNTRUST BANK, as co-documentation agents (in such capacity,
together with their successors and assigns in such capacity, the "Documentation
Agents"); and DEUTSCHE BANK ALEX. BROWN INC. and BANK OF AMERICA, N.A., as
co-syndication agents (in such capacity, together with their successors and
assigns in such capacity, the "Syndication Agents").

                                    RECITALS

         A.       The Borrower, the Lenders, the Agent, the Syndication Agents
and the Documentation Agents are parties to an Amended and Restated Credit
Agreement dated as of June 19, 2001, as amended pursuant to that certain letter
agreement dated as of April 2, 2002, the First Amendment to Credit Agreement
dated as of April 30, 2002, that certain letter agreement dated as of May 16,
2002, the Second Amendment to Credit Agreement dated as of October 1, 2002, the
Third Amendment to Credit Agreement dated as of December 30, 2002, and that
certain letter agreement dated as of November 20, 2003 (as so amended, the
"Credit Agreement"). Capitalized terms used herein without definition have the
meanings assigned to them in the Credit Agreement.

         B.       The Borrower has requested that the Credit Agreement be
amended to permit the prepayment or redemption of certain Subordinated Debt.

         C.       The Lenders signing below are willing to consent to such
amendment on the terms and conditions hereinafter set forth.

         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:

I.       AMENDMENTS TO CREDIT AGREEMENT. Subject to the satisfaction of each of
the conditions set forth herein, the Credit Agreement is hereby amended as
follows:

         A.       Definitions. Section 1.1 of the Credit Agreement is amended as
follows:

                  1.       By inserting the following new definition in
         alphabetical order:

<PAGE>

                           "Convertible Subordinated Notes": the $250,000,000 in
                  4.50% Convertible Subordinated Notes due June 1, 2009 issued
                  by LifePoint Parent on or about May 22, 2002.

                  2.       By amending and restating the definition of
         "Subordinated Debt" as follows:

                           "Subordinated Debt": the High Yield Offering, the
                  Convertible Subordinated Notes, and any other Indebtedness of
                  Borrower or any of its Subsidiaries subordinated on terms
                  satisfactory to the Administrative Agent and the Required
                  Lenders pursuant to written agreements in form and substance
                  satisfactory to the Administrative Agent.

         B.       Restricted Payments. Section 7.6 of the Credit Agreement is
hereby amended by deleting the period at the end of subparagraph (j) thereof,
adding the character and word "; and" after such subparagraph (j), and adding
the following subparagraph (k) thereafter:

                  "(k)     Borrower shall be permitted to prepay, redeem,
         defease, repurchase or otherwise acquire up to an aggregate amount of
         $150,000,000 of its Convertible Subordinated Notes, unless on the date
         of any such proposed prepayment, redemption, defeasance, repurchase or
         other acquisition (or, if earlier, on the date Borrower becomes
         obligated to consummate such transaction) or after giving effect
         thereto, an Event of Default shall have occurred and be continuing."

         C.       No Further Amendments. Except as specifically amended hereby,
the text of the Credit Agreement and all other Loan Documents shall remain
unchanged and in full force and effect.

II.      REFERENCES IN SECURITY DOCUMENTS; CONFIRMATION OF SECURITY. All
references to the "Credit Agreement" in all Security Documents, and in any other
Loan Documents shall, from and after the date hereof, refer to the Credit
Agreement, as amended by this Amendment, and all obligations of the Loan Parties
under the Loan Documents shall be secured by and be entitled to the benefits of
said Security Documents and such other Loan Documents. All Security Documents
heretofore executed by any of the Loan Parties shall remain in full force and
effect and, by the Borrower's signature hereto and each other Loan Party's
consent hereto, such Security Documents are hereby ratified and affirmed.

III.     REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE BORROWER. The Borrower
hereby represents and warrants to, and covenants and agrees with, the Lenders
that:

         A.       The execution and delivery of this Amendment have been duly
authorized by all requisite company action on the part of the Borrower.

         B.       The representations and warranties of each of the Loan Parties
contained in the Credit Agreement and the other Loan Documents are true and
correct in all material respects on and as of the date of this Amendment as
though made at and as of such date. Since the Closing

                                     - 2 -

<PAGE>

Date, no event or circumstance has occurred or existed which could reasonably be
expected to have a Material Adverse Effect. As of the date hereof and after
giving effect to this Amendment, no Default has occurred and is continuing.

         C.       No Loan Party is required to obtain any consent, approval or
authorization from, or to file any declaration or statement with, any
governmental instrumentality or other agency or any other person or entity in
connection with or as a condition to the execution, delivery or performance of
this Amendment.

         D.       This Amendment constitutes the legal, valid and binding
obligation of each Loan Party signatory hereto, enforceable against it in
accordance with their respective terms, subject to bankruptcy, insolvency,
reorganization, moratorium and similar laws affecting the rights and remedies of
creditors generally or the application of principles of equity, whether in any
action at law or proceeding in equity, and subject to the availability of the
remedy of specific performance or of any other equitable remedy or relief to
enforce any right thereunder.

         E.       The Borrower will satisfy all of the conditions set forth in
SECTION IV.

IV.      CONDITIONS. The willingness of the Agent and the Lenders to amend the
Credit Agreement as provided above is subject to the following conditions
precedent and subsequent:

         A.       The Borrower shall have executed and delivered to the Agent
(or shall have caused to be executed and delivered to the Agent by the
appropriate persons) the following:

                  1.       On or before the date hereof:

                           (a) This Amendment;

                           (b) The Consent and Confirmation of Security of
                  Parent and the Consent and Confirmation of Security of
                  Subsidiaries attached hereto; and

                           (c) True and complete copies of any required
                  stockholders' and/or directors' consents and/or resolutions,
                  authorizing the execution and delivery of this Amendment,
                  certified by the Secretary of the Borrower.

                  2.       Such other supporting documents and certificates as
         the Agent or its counsel may reasonably request within the time
         period(s) reasonably designated by the Agent or its counsel.

         B.       All legal matters incident to the transactions hereby
contemplated shall be reasonably satisfactory to the Agent's counsel.

V.       MISCELLANEOUS.

         A.       As provided in the Credit Agreement, the Borrower agrees to
reimburse the Agent upon demand for all reasonable fees and disbursements of
counsel to the Agent incurred in connection with the preparation of this
Amendment.

                                     - 3 -

<PAGE>

         B.       This Amendment shall be governed by and construed in
accordance with the laws of the State of New York.

         C.       This Amendment may be executed by the parties hereto in
several counterparts hereof and by the different parties hereto on separate
counterparts hereof, all of which counterparts shall together constitute one and
the same agreement. Delivery of an executed signature page of this Amendment by
facsimile transmission shall be effective as an in-hand delivery of an original
executed counterpart hereof.

                    [The next pages are the signature pages.]

                                     - 4 -

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed as a sealed instrument by their duly authorized representatives,
all as of the day and year first above written.

                                   LIFEPOINT HOSPITALS HOLDINGS, INC.

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   FLEET NATIONAL BANK,
                                   as Administrative Agent and a Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   BANK OF AMERICA, N.A.,
                                   as Co-Syndication Agent and a Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   DEUTSCHE BANK SECURITIES INC.,
                                   as Co-Syndication Agent

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   CREDIT LYONNAIS NEW YORK BRANCH,
                                   as Co-Documentation Agent and a Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                             (signatures continued)

                                              Signature Page to Fourth Amendment

<PAGE>

                                   SUNTRUST BANK,
                                   as Co-Documentation Agent and a Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   DEUTSCHE BANK TRUST COMPANY AMERICAS,
                                   as a Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   CREDIT SUISSE FIRST BOSTON,
                                   as a Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   U.S. BANK NATIONAL
                                   ASSOCIATION, as a Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                             (signatures continued)

                                              Signature Page to Fourth Amendment

<PAGE>

                                   NATIONAL CITY BANK OF KENTUCKY,
                                   as a Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   MERRILL LYNCH CAPITAL CORPORATION, as a
                                   Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                   GENERAL ELECTRIC CAPITAL CORPORATION, as a
                                   Lender

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

                                              Signature Page to Fourth Amendment

<PAGE>

                 CONSENT AND CONFIRMATION OF SECURITY OF PARENT

         The undersigned, LIFEPOINT HOSPITALS, INC., which owns all of the
issued and outstanding equity interests in the Borrower, hereby joins in the
execution of the foregoing Fourth Amendment to Credit Agreement dated as of June
18, 2004 (the "Amendment") to which this Consent is attached (1) to confirm its
consent to all of the transactions contemplated by the Amendment, and (2) to
confirm and ratify its Amended and Restated Guarantee Agreement and Security
Agreement entered into as required under such Credit Agreement and dated as of
June 19, 2001 in favor of the Agent and the Lenders which remains in full force
and effect.

                                   LIFEPOINT HOSPITALS, INC.

                                   By: _________________________________________
                                       Name: ___________________________________
                                       Title: __________________________________

<PAGE>

              CONSENT AND CONFIRMATION OF SECURITY OF SUBSIDIARIES

         Each of the undersigned Subsidiaries of the Borrower hereby joins in
the execution of the foregoing Fourth Amendment to Credit Agreement dated as of
June 18, 2004 (the "Amendment") to which this Consent and Confirmation of
Security of Subsidiaries is attached (1) to confirm its consent, to the extent
required, to all of the transactions contemplated by the Amendment, and (2) to
confirm and ratify, as applicable, its Amended and Restated Guarantee and
Security Agreement entered into as required under such Credit Agreement and
dated as of June 19, 2001 with the Agent, on behalf of the Lenders, or its
Guarantee and Pledge Agreement entered into under such Credit Agreement and
dated as of July 30, 2001, each of which remain in full force and effect with
respect to all of the Borrower Obligations and Grantor Obligations (as defined
therein).

                                           AMERICA GROUP OFFICES, LLC
                                           AMERICA MANAGEMENT COMPANIES, LLC
                                           AMG-CROCKETT, LLC
                                           AMG-HILCREST, LLC
                                           AMG-HILLSIDE, LLC
                                           AMG-LIVINGSTON, LLC
                                           AMG-LOGAN, LLC
                                           AMG-SOUTHERN TENNESSEE, LLC
                                           AMG-TRINITY, LLC
                                           ASHLEY VALLEY MEDICAL CENTER, LLC
                                           ASHLEY VALLEY PHYSICIAN PRACTICE, LLC
                                           ATHENS PHYSICIAN PRACTICE, LLC
                                           ATHENS REGIONAL MEDICAL CENTER, LLC
                                           BARROW MEDICAL CENTER, LLC
                                           BARTOW GENERAL PARTNER, LLC
                                           BARTOW HEALTHCARE SYSTEM LTD
                                           BARTOW MEMORIAL LIMITED PARTNER, LLC
                                           BOURBON COMMUNITY HOSPITAL, LLC
                                           BOURBON PHYSICIAN PRACTICE, LLC
                                           BUFFALO TRACE RADIATION ONCOLOGY
                                              ASSOCIATES, LLC
                                           BURDICK WEST PHYSICIAN PRACTICE, LLC
                                           CASTLEVIEW HOSPITAL, LLC
                                           CASTLEVIEW MEDICAL, LLC
                                           CASTLEVIEW PHYSICIAN PRACTICE, LLC
                                           COMMUNITY HOSPITAL OF ANDALUSIA, INC.
                                           COMMUNITY MEDICAL, LLC
                                           CROCKETT HOSPITAL, LLC
                                           CROCKETT PHO, LLC
                                           DODGE CITY HEALTHCARE GROUP, L.P.
                                           DODGE CITY HEALTHCARE PARTNER, INC.

                             (signatures continued)

<PAGE>

                                        GEORGETOWN COMMUNITY HOSPITAL, LLC
                                        GEORGETOWN REHABILITATION, LLC
                                        GUYAN VALLEY HOSPITAL, LLC
                                        HALSTEAD HOSPITAL, LLC
                                        HCK LOGAN MEMORIAL, LLC
                                        HDP ANDALUSIA, LLC
                                        HDP GEORGETOWN, LLC
                                        HILLSIDE HOSPITAL, LLC
                                        HST PHYSICIAN PRACTICE, LLC
                                        HTI GEORGETOWN, LLC
                                        HTI PINELAKE, LLC
                                        INTEGRATED PHYSICIAN SERVICES, LLC
                                        KANSAS HEALTHCARE MANAGEMENT
                                          COMPANY, INC.
                                        KANSAS HEALTHCARE MANAGEMENT
                                           SERVICES, LLC
                                        KENTUCKY HOSPITAL, LLC
                                        KENTUCKY MEDSERV, LLC
                                        KENTUCKY MSO, LLC
                                        KENTUCKY PHYSICIANS SERVICES, INC.
                                        LAKE CUMBERLAND REGIONAL HOSPITAL,
                                           LLC
                                        LAKE CUMBERLAND REGIONAL PHYSICIAN
                                           HOSPITAL ORGANIZATION, LLC
                                        LAKELAND COMMUNITY HOSPITAL, LLC
                                        LANDER VALLEY MEDICAL CENTER, LLC
                                        LANDER VALLEY PHYSICIAN PRACTICE, LLC
                                        LHSC, LLC
                                        LIFEPOINT ASSET MANAGEMENT COMPANY, INC.
                                        LIFEPOINT CORPORATE SERVICES, GENERAL
                                           PARTNERSHIP
                                        LIFEPOINT CSGP, LLC
                                        LIFEPOINT CSLP, LLC
                                        LIFEPOINT HOLDINGS 2, LLC
                                        LIFEPOINT HOLDINGS 3, INC.
                                        LIFEPOINT OF GAGP, LLC
                                        LIFEPOINT OF GEORGIA, LIMITED
                                           PARTNERSHIP
                                        LIFEPOINT OF KENTUCKY, LLC
                                        LIFEPOINT OF LAKE CUMBERLAND, LLC
                                        LIFEPOINT MEDICAL GROUP-HILLSIDE, INC.
                                        LIFEPOINT RC, INC.
                                        LIVINGSTON REGIONAL HOSPITAL, LLC
                                        LOGAN GENERAL HOSPITAL, LLC

                             (signatures continued)

<PAGE>

                                        LOGAN HEALTHCARE PARTNER, LLC
                                        LOGAN MEDICAL, LLC
                                        LOGAN MEMORIAL HOSPITAL, LLC
                                        LOGAN PHYSICIAN PRACTICE, LLC
                                        MEADOWVIEW PHYSICIAN PRACTICE, LLC
                                        MEADOWVIEW REGIONAL MEDICAL CENTER, LLC
                                        MEADOWVIEW RIGHTS, LLC
                                        NORTHWEST MEDICAL CENTER-WINFIELD, LLC
                                        NWMC-WINFIELD PHYSICIAN PRACTICE, LLC
                                        PINELAKE PHYSICIAN PRACTICE, LLC
                                        PINELAKE REGIONAL HOSPITAL, LLC
                                        POITRAS PRACTICE, LLC
                                        PUTNAM COMMUNITY MEDICAL CENTER, LLC
                                        R. KENDALL BROWN PRACTICE, LLC
                                        RIVERTON MEMORIAL HOSPITAL, LLC
                                        RIVERTON PHYSICIAN PRACTICES, LLC
                                        RIVERVIEW MEDICAL CENTER, LLC
                                        RUSSELLVILLE HOSPITAL, LLC
                                        RUSSELLVILLE PHYSICIAN PRACTICES, LLC
                                        SELECT HEALTHCARE, LLC
                                        SILETCHNIK PRACTICE, LLC
                                        SMITH COUNTY MEMORIAL HOSPITAL, LLC
                                        SOMERSET SURGERY PARTNER, LLC
                                        SOUTHERN TENNESSEE EMS, LLC
                                        SOUTHERN TENNESSEE MEDICAL CENTER, LLC
                                        SOUTHERN TENNESSEE PHO, LLC
                                        SPRINGHILL MEDICAL CENTER, LLC
                                        SPRINGHILL MOB, LLC
                                        SPRINGHILL PHYSICIAN PRACTICE LLC
                                        SPRING VIEW HOSPITAL, LLC
                                        THM PHYSICIAN PRACTICE, LLC
                                        VILLE PLATTE MEDICAL CENTER, LLC
                                        WEST VIRGINIA PHYSICIAN PRACTICE, LLC
                                        WESTERN PLAINS REGIONAL HOSPITAL, LLC
                                        WOODFORD HOSPITAL, LLC
                                        WYOMING HOLDINGS, LLC

                                   By: _________________________________________
                                        Name: __________________________________
                                        Title: _________________________________
                                        (duly authorized signatory as to all)<PAGE>
                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                                                                   Exhibit 10.15

                                SUPPLY AGREEMENT

THIS AGREEMENT is made this 1st day of January, 2000 by and between

DIOSYNTH B.V., having its registered office at Kloosterstraat 6, 5349 AB Oss,
the Netherlands (hereinafter referred to as "Diosynth"),

and

PHARMACEUTICAL DISCOVERY CORPORATION, having its offices at 33 West Main Street,
Elmsford, NY 10523, USA, hereinafter referred to as "PDC").

WHEREAS

-     Diosynth is engaged in the development, manufacture and sale of, amongst
      other, recombinant human Insulin;

-     PDC is engaged in the development of its proprietary formulation of
      insulin and upon successful development wishes to commercialize or have
      commercialized such formulation;

-     PDC wishes to purchase from Diosynth recombinant human insulin to be used
      in its formulation and Diosynth is willing to sell and supply the
      recombinant human insulin to PDC on the terms and conditions as set forth
      herein.

NOW THEREFORE, parties hereto agree as follows:

ARTICLE 1.SUPPLY

1.1   Diosynth agrees to supply PDC and PDC herewith agrees to purchase from
      Diosynth recombinant human insulin as further specified in Appendix A
      attached to this Agreement (hereinafter referred to as "Product").

1.2   During the development of the insulin formulation by PDC, Diosynth will
      supply PDC with the Product in such quantities as PDC shall order
      estimated not to exceed the following:

      [...***...]
      [...***...]
      [...***...]
      [...***...]
      [...***...]
      [...***...]
      [...***...]

1.3   In case the insulin formulation is developed successfully and in the event
      PDC wishes to sell its insulin formulation on a commercial basis, Diosynth
      will supply PDC with the Product in such quantities as PDC shall order.

      It is foreseen that PDC will indicate the following quantities as its
      estimated commercial needs for the Product.

      [...***...]
      [...***...]
      [...***...]
      [...***...]

                                              * CONFIDENTIAL TREATMENT REQUESTED
                                       1
<PAGE>
ARTICLE 2. ORDERS AND DELIVERY

2.1   Within fifteen (15) days from the beginning of each calendar quarter, PDC
      shall furnish to Diosynth a rolling forecast of its requirements of the
      Product, together with the delivery dates, during the next four (4)
      calendar quarters whereby the required quantities for the first quarter
      shall be a firm purchase order for the supply of the Product and shall not
      deviate more than twenty (20) percent from the preceding forecast provided
      to Diosynth.

2.2   Diosynth will deliver the Product to PDC within the date stipulated in the
      firm purchase order. Diosynth will use its best commercial efforts to
      deliver as soon as possible any quantities in excess of the purchase order
      as determined in Article 2.1.

2.3   Delivery of each batch of Product shall be effectuated FOB PDC's
      manufacturing facility (INCOTERMS 2000).

2.4   Each shipment of the Product shall be accompanied by relevant certificates
      of analysis and an invoice.

ARTICLE 3. PRODUCT QUALITY

3.1   Diosynth warrants that the Product delivered under this Agreement to PDC
      shall conform to the specifications set forth In Appendix A and shall be
      manufactured according to applicable regulations of Good Manufacturing
      Practices.

3.2   Within at most thirty (30) days of delivery of batches of the Product, PDC
      shall inform Diosynth of any nonconformity of the delivered batches with
      the specifications as set forth in Appendix A hereto. If Diosynth agrees
      with PDC's opinion, PDC shall dispose of the defective delivery as
      Dlosynth shall direct and at Diosynth's expense and Diosynth shall replace
      such delivery free of charge as soon as practical thereafter. If PDC falls
      to notify Diosynth of its faulty manufacture within thirty (30) days from
      the date of delivery of any quantity of Product, this delivery shall be
      deemed to conform to the specifications for the purpose of this Article 4.

      If the parties fail to agree on whether a delivery is defective or on the
      responsibility therefor, the matter shall be finally determined by an
      independent expert to be nominated by agreement between the parties. The
      expert's opinion shall be binding upon the parties and his fees and
      expenses shall be borne by the party against which the expert's opinion is
      given. If the expert's opinion is not wholly in favor of one party, the
      parties shall share the costs equally.

ARTICLE 4. USE

      PDC shall use the Product only in compliance with regulatory approvals
      and, in the absence of regulatory approvals, only in connection with
      research and the development of the insulin formulation.

ARTICLE 5. REGULATORY ISSUES

5.1   Diosynth agrees to file, at no costs to PDC and not later then December
      31, 2001, a US Drug Master File and any similar filing required in Canada
      and the European Union covering the manufacture of the Product.

5.2   Diosynth will cooperate with PDC and, without limitation, further support
      PDC with all other possible and reasonable regulatory information during
      the term of this agreement.

                                       2
<PAGE>

ARTICLE 6. INDEMNIFICATION

6.1   PDC shall indemnify and hold Diosynth harmless against all claims made
      and/or suits brought against Diosynth by third parties in respect of any
      personal loss, damage or injury arising or resulting result from the use
      of the Product or the formulation developed and sold by PDC, except in
      case that any such personal loss, damage or injury arises or results from
      the faulty manufacture by Diosynth.

6.2   Diosynth shall indemnify and hold PDC harmless against all claims made
      and/or suits brought against PDC by third parties in respect of any
      personal loss, damage or injury arising or resulting or alleged to
      directly arise or result from the appropriate use of the Product in so far
      as in any particular case such personal loss, damage or injury is
      attributable to faulty manufacture by Diosynth.

6.3   In no event shall either party be liable for any consequential damages,
      costs, and losses whatsoever endured by the other.

ARTICLE 7. PRICE AND PAYMENT

7.1   For the quantities to be supplied by Diosynth in 2000, PDC shall pay the
      purchase price of [...***...], whereas for supply of the quantities in
      2001 and 2002 the purchase price will be [...***...].

7.2   Diosynth is willing to accept a purchase price of [...***...] as the
      commercial market price in the year 2000. In this respect "commercial
      market price" is considered to be the price for quantities as described in
      Article 1.3. This commercial market price in the year 2000 will be used as
      a basis for the determination of the commercial market price in subsequent
      years. To that end, on or before September 30 of each calendar year,
      parties will in good faith determine the commercial market price for the
      product for the following calendar year. In any case the purchase price
      will not increase, on a year by year basis, with more than the increase of
      the labor cost index in the Netherlands, as published by the C.B.S.
      (Centraal Bureau voor de Statistiek"). In addition, the price to PDC will
      not be higher than to any other customer as long as the quality and the
      quantity of the Product to that other customer is substantially comparable
      with the quantity and quality of the Product supplied to PDC.

7.3   Payment of the Product delivered shall be made by PDC within thirty (30)
      days of the date of invoice or receipt of the Product, whichever shall
      last occur.

ARTICLE 8. INFORMATION, SECRECY AND NON-USE

8.1   Upon signature of this Agreement and during the term thereof, Diosynth
      shall provide PDC with all information and documentation about the Product
      necessary for the development of the insulin formulation.

8.2   Each party shall keep strictly confidential and not use, except for the
      purpose and during the course of this Agreement, nor disclose, except to
      governmental authorities for registration purposes, any information which
      it receives from the other and which is marked confidential. Each party
      shall impose such confidentiality obligation on its employees.

8.3   This confidentiality obligation does not apply to any part of the
      confidential information which

      -     at present is publicly known or thereafter becomes publicly known
            through no fault of the receiving party,
      -     is already known by the receiving party on the date of disclosure,
            provided such prior knowledge can be adequately substantiated by
            documentation;
      -     properly and lawfully becomes available to the receiving party from
            a third party.

8.4   For the purpose of the development of the formulation PDC shall be
      entitled to disclose information to third parties provided that these
      third parties shall be bound by substantially the same secrecy obligations
      as contained herein.

                                             *  CONFIDENTIAL TREATMENT REQUESTED

                                       3
<PAGE>

ARTICLE 9. TERM AND TERMINATION

9.1   This Agreement shall become effective as of January 1st, 2000 and shall
      continue to be in force until terminated as provided herein.

9.2   Notwithstanding the preceding paragraph, this Agreement may be terminated
      forthwith by registered or certified mail:

      a)    By both parties for any reason or no reason with a two year written
            notice; or
      b)    by either party in the event the other party shall substantially
            breach any of its obligations under this Agreement and shall fail to
            remedy such breach within sixty (60) days from receipt of written
            notice or such breach by the party not in default; or
      c)    by either party in the event of the other party's liquidation,
            bankruptcy or state of insolvency; or
      d)    by PDC, with 30 days written notice if a controlling regulatory
            authority either fails to approve or withdraws approval of the
            insulin formulation. In the event that the product is withdrawn by
            regulatory decree in a portion, but not all of the market, then PDC
            shall have the right to reduce the minimum quantities with 30 days
            written notice.

9.3   In the event Diosynth terminates this Agreement pursuant to article 9.2a)
      and Diosynth is PDC's sole source of supply for the Product, Diosynth
      shall have the responsibility to qualify an alternative source of supply,
      based on Diosynth's manufacturing process, which should enable PDC to
      continue its commercial activities with respect to the Product without
      interruption or disadvantage.

ARTICLE 10. FORCE MAJEURE

Neither party shall be responsible for failure or delay in performance of any of
its obligations under the Agreement due to force majeure such as war,
insurrection, strikes, lockouts, acts of God, governmental action, or any other
contingency beyond its reasonable control.

ARTICLE 11. HARDSHIP

Should it appear that at any time during the lifetime of this Agreement and for
any reason, the terms of this Agreement are not workable from an economical
point of view, the parties to this Agreement at the request of the party
concerned shall meet within two (2) months from the date of that request and
expend their best efforts to re-establish the terms of this Agreement in a
mutually satisfactory way.

ARTICLE 12. MISCELLANEOUS

12.1  This Agreement shall be governed by and construed in accordance with the
      laws of England applicable to agreements executed and to be performed
      therein.

12.2  All disputes arising in connection with the present Agreement, which
      cannot be settled amicably, shall be finally settled by the competent
      court of London, England. The prevailing party shall be entitled to
      recover its legal fees and expenses.

12.3  No amendment and/or modification of this Agreement shall be valid unless
      it is laid down in writing and signed by both parties.

12.4  All appendices attached hereto shall form an integral part of this
      Agreement. Parties may from time to time update these Appendices if so
      required.

                                       4
<PAGE>
AS AGREED UPON and signed in duplicate

Oss,                                       Elmsford,

Diosynth B.V.                              Pharmaceutical Discovery Corporation

/s/  A. Sanders                            /s/  Solomon S. Steiner
-------------------------------------      -------------------------------------
A. Sanders                                 Solomon S. Steiner, PhD
Managing Director                          CEO and Chairman

/s/  P. van Straelen                       /s/  Per Fog
-------------------------------------      -------------------------------------
P. van Straelen                            Per B. Fog
Sales & Marketing Manager                  President & CFO

                                       5
<PAGE>
                                   APPENDIX A

                         Specifications of the Product

The product complies with the specifications as described in USP 24.

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]